Proteome Sciences (AQSE:PRM.GB) EBIT : £-3.16 Mil (TTM As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Proteome Sciences EBIT?

Proteome Sciences's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was £-1.71 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was £-3.16 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Proteome Sciences's annualized ROC % for the quarter that ended in Jun. 2024 was -18.16%. Proteome Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -93.93%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Proteome Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -15.64%.

Proteome Sciences EBIT Historical Data

The historical data trend for Proteome Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteome Sciences EBIT Chart

Proteome Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

0.30

0.55

0.41

1.73

-1.62

Proteome Sciences Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial															0.27	1.46	-0.16	-1.46	-1.71

Competitive Comparison of Proteome Sciences's EBIT

For the Diagnostics & Research subindustry, Proteome Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proteome Sciences's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Proteome Sciences's EV-to-EBIT falls into.

Proteome Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-3.16 Mil.

Proteome Sciences (AQSE:PRM.GB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Proteome Sciences's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-3.412 * ( 1 - -3.03% )	/	( (19.319	+	19.395)	/ 2 )
=	-3.5153836	/	19.357
=	-18.16 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.458	-	0.449	-	( 2.027	-	max(0, 12.474	-	4.164	+	2.027	))
=	19.319

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.454	-	0.675	-	( 1.208	-	max(0, 13.223	-	2.607	+	1.208	))
=	19.395

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Proteome Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-3.412	/	( ( (3.075 + max(1.084, 0))	+	(2.629 + max(0.477, 0)) )	/	2 )
=	-3.412	/	( ( 4.159	+	3.106 )	/	2 )
=	-3.412	/	3.6325
=	-93.93 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.705	+	0.837	+	0.172)	-	(0.449	+	0	+	0.181)
=	1.084

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.38	+	0.772	+	0)	-	(0.675	+	0	+	0)
=	0.477

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Proteome Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-3.164	/	20.235
	=	-15.64 %

Proteome Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Proteome Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Proteome Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Proteome Sciences PLC (AQSE:PRM.GB) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

PMSNF:USA PRM:UK

Address

Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP

Website

https://www.proteomics.com

Proteome Sciences PLC is protein biomarker research and development. provider of contract research services for the identification, validation and application of protein biomarkers. Its only reportable segment is the sale of goods and biomarker services. It generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Other.

Proteome Sciences Headlines

No Headlines